Nelarabine
- Generic Name
- Nelarabine
- Brand Names
- Arranon, Atriance
- Drug Type
- Small Molecule
- Chemical Formula
- C11H15N5O5
- CAS Number
- 121032-29-9
- Unique Ingredient Identifier
- 60158CV180
- Background
Nelarabine is an antineoplastic agent that is typically used to treat acute T-cell lymphoblastic leukemia, particularly T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), in both adult and pediatric patients whose disease has not responded to or has relapsed following at least two chemotherapy regimens. T-cell acute lympho...
- Indication
ARRANON is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
- Associated Conditions
- T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
- Associated Therapies
- -
Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 343
- Registration Number
- NCT01376115
- Locations
- ๐ฏ๐ต
University of Tsukuba Hospital, Tsukuba, Japan
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
- First Posted Date
- 2010-03-29
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT01094860
- Locations
- ๐บ๐ธ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Biological: rituximabBiological: paliferminDrug: cyclophosphamideProcedure: allogeneic hematopoietic stem cell transplantationDrug: cytarabineDrug: daunorubicin hydrochlorideRadiation: total-body irradiationDrug: etoposideDrug: fludarabine phosphateDrug: imatinib mesylateDrug: melphalanDrug: mercaptopurineDrug: methotrexateDrug: nelarabineDrug: pegaspargaseDrug: vincristine sulfate
- First Posted Date
- 2010-03-12
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- University College, London
- Target Recruit Count
- 1033
- Registration Number
- NCT01085617
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2020-10-01
- Target Recruit Count
- 23
- Registration Number
- NCT00981799
- Locations
- ๐บ๐ธ
Childrens Hospital Los Angeles, Los Angeles, California, United States
๐บ๐ธUniversity of Texas at Southwestern, Dallas, Texas, United States
๐บ๐ธUniversity of Miami Cancer Center, Miami, Florida, United States
Observational Study of Nelarabine in Children and Young Adults
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT00866671
- Locations
- ๐ช๐ธ
GSK Investigational Site, Madrid, Spain
506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 120
- Registration Number
- NCT00684619
- Locations
- ๐ฉ๐ช
Universitรคtsklinikum Essen, Essen, NRW, Germany
๐ฉ๐ชRobert Bosch Krankenhaus, Stuttgart, Baden-Wรผrttemberg, Germany
๐ฉ๐ชUniversity Hospital of Frankfurt, Medical Dept. II, Frankfurt, Hessen, Germany
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 160
- Registration Number
- NCT00501826
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
- Conditions
- Interventions
- Other: Laboratory Biomarker AnalysisDrug: CyclophosphamideDrug: AsparaginaseDrug: Daunorubicin HydrochlorideDrug: CytarabineDrug: MercaptopurineDrug: Leucovorin CalciumDrug: DexamethasoneDrug: PegaspargaseDrug: Doxorubicin HydrochlorideDrug: MethotrexateDrug: NelarabineDrug: PrednisoneDrug: Vincristine SulfateRadiation: Radiation TherapyDrug: Thioguanine
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1895
- Registration Number
- NCT00408005
- Locations
- ๐บ๐ธ
Scott and White Memorial Hospital, Temple, Texas, United States
๐บ๐ธHenry Ford Health Saint John Hospital, Detroit, Michigan, United States
๐บ๐ธChildren's Hospital of Alabama, Birmingham, Alabama, United States
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
- Conditions
- Angioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaSplenic Marginal Zone LymphomaWaldenstrรถm Macroglobulinemia
- Interventions
- First Posted Date
- 2004-04-20
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 111
- Registration Number
- NCT00005950
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
506U78 in Treating Patients With Lymphoma
- Conditions
- Anaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeSmall Intestine LymphomaStage I Cutaneous T-cell Non-Hodgkin LymphomaStage I Mycosis Fungoides/Sezary SyndromeStage II Cutaneous T-cell Non-Hodgkin LymphomaStage II Mycosis Fungoides/Sezary Syndrome
- Interventions
- First Posted Date
- 2004-04-19
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 74
- Registration Number
- NCT00005080
- Locations
- ๐บ๐ธ
Cancer and Leukemia Group B, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.